ArticlePolymer science & technology (Washington, D.C.)2026
Harnessing Self-Assembling Peptides on γδ T Cells to Enhance Anti-Tumor Immunity.
Article in Polymer science & technology (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
γδ T cells possess significant anti-tumor potential; however, the expression of immune checkpoint molecules on tumor cells often leads to functional exhaustion of these T cells, resulting in variable outcomes in clinical trials. Targeting these immune checkpoints may alleviate the inhibitory effects of the tumor microenvironment on γδ T cell functionality. In this study, we developed a PD-L1-targeting peptide conjugated with maleimide, facilitating self-assembly on the surface of γδ T cells to form fibrous structures via Michael addition reactions with thiol groups on the cell membrane. Our findings demonstrate that this peptide effectively binds and self-assembles without impairing the proliferation or effector functions of γδ T cells. Notably, peptide-modified γδ T cells exhibited enhanced cytotoxic activity against tumor cells in vitro and significantly inhibited tumor growth in vivo. Furthermore, these modified γδ T cells promoted the infiltration of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.